Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3009 in Advanced Small Cell Lung Cancer
NCT06613009Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Dec 2024
- Primary completion
- Aug 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of IBI3009 in small cell lung cancer (SCLC), sponsored by Innovent Biologics. Primary endpoints: Number of subjects with adverse events up to 3 years, Number of subjects with clinically significant changes in physical examination results up to 3 years and 3 more. Started Dec 2024; status: recruiting.
02
Drugs
IBI3009
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06613009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613009.